Abstract
Pulmonary hypertension is a daunting accompaniment of advanced heart failure. Efforts to safely and consistently lower pulmonary vascular resistance are necessary but fraught with challenges. In this report the authors explore the novel use of sildenafil, an inhibitor of phosphodiesterase-5, in tackling pulmonary hypertension in heart failure. The salutary effects of this agent deserve further study. © 2003 CHF, Inc.
Cite
CITATION STYLE
Alaeddini, J., Uber, P., Park, M. H., Scott, R. L., & Mehra, M. R. (2003). Sildenafil and assessment of pulmonary arterial reactivity in heart failure. Congestive Heart Failure, 9(3), 176–178. https://doi.org/10.1111/j.1527-5299.2003.02394.x
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.